Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Extramedullary disease (EMD): A common terminal pathway in multiple myeloma (MM) progression.

(2017) S. Z. Usmani et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

(2011) J. D. Shaughnessy et al.   BLOOD

Could CR mean cure?

(2011) B. Barlogie et al.   BLOOD

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Approach to the treatment of multiple myeloma: a clash of philosophies

(2011) S. V. Rajkumar et al.   BLOOD

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings

(2011) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Can multiple myeloma become a curable disease?

(2011) J. F. San-Miguel et al.   HAEMATOLOGICA

Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

(2011) Joan Bladé et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Refining "total therapy" for myeloma

(2010) J. Blade et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

(2010) A. Broyl et al.   BLOOD

Gastroduodenal Ulcerations As a Delayed Complication of Hepatic Metastasis Radioembolization

(2010) Jayan Nair et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

(2009) B. Nair et al.   BLOOD

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

(2009) A. Hoering et al.   BLOOD

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

(2009) T. B. Bartel et al.   BLOOD

Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile

(2009) Yiming Zhou et al.   BRITISH JOURNAL OF HAEMATOLOGY

TP53deletion is not an adverse feature in multiple myeloma treated with total therapy 3

(2009) John D. Shaughnessy et al.   BRITISH JOURNAL OF HAEMATOLOGY

The molecular characterization and clinical management of multiple myeloma in the post-genome era

(2009) Y Zhou et al.   LEUKEMIA

Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

(2008) Shaji K. Kumar et al.   BRITISH JOURNAL OF HAEMATOLOGY

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

(2008) A Dispenzieri et al.   LEUKEMIA